In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Lannett Company, Inc.

https://www.lannett.com/

Latest From Lannett Company, Inc.

Generics Industry Counts Cost Of Stormy Second Quarter

As the global generics industry had predicted, the unexpected growth seen in the first quarter of 2020 due to forward buying caused by COVID-19 levelled off in the second quarter. However, a few companies managed to report a “mixed” second quarter or a positive first half for 2020, even after experiencing challenges, such as operational interruptions, posed by the pandemic.

Coronavirus COVID-19 Generic Drugs

Lannett Confident Of $1bn In Sales By 2025

US-centric generics player Lannett has an ambitious sales and profitability goals for the next five years, driven by several rewarding pipeline opportunities and a leaner cost base. CEO Tim Crew told investors of Lannett’s plans as he presented year-end financial results

Strategy Sales & Earnings

Lannett Makes Deal For Respirent’s Flovent Diskus Rival

Lannett has partnered with China’s Respirent for a generic version of GlaxoSmithKline’s Flovent Diskus. At the same time, the US company has extended its exclusive US distribution rights for Respirent’s Advair Diskus rival from 10 years to 12 years, as Lannett remains on track to file its ANDA this calendar year.

Deals Generic Drugs

Deal Watch: Roche Partners With Jnana On Cellular Metabolism Approach To Disease

Pharma and the US biotech will target key regulators of cellular metabolism with focus on immune and neurological disorders. Royalty Pharma buys portion of PTC’s royalty rights to risdiplam, under development at Roche.

Deals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
  • Other Names / Subsidiaries
    • Kremers Urban Pharmaceuticals, Cody Laboratories, Silarx Pharmaceuticals
UsernamePublicRestriction

Register